| fluvoxamine / Generic mfg. |
| Completed | 1 | 12 | Europe | sildenafil, fluvoxamine | Heidelberg University | Healthy | | 11/04 | | |
| Completed | 1 | 30 | US | AV650, Fluvoxamine, Paroxetine | Avigen | Healthy | | 05/07 | | |
NCT01299415: Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor |
|
|
| Terminated | 1 | 17 | US | Vadimezan™, ASA404 | Novartis Pharmaceuticals | Solid Tumors | 09/10 | | | |
NCT01908296: Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers |
|
|
| Completed | 1 | 24 | Japan | FK949E, extended release formulation of quetiapine, fluvoxamine, Luvox® | Astellas Pharma Inc | Healthy, Pharmacokinetics of Quetiapine | 08/11 | 08/11 | | |
NCT01540500: Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine |
|
|
| Completed | 1 | 24 | US | Tasimelteon, VEC-162, BMS-214778, Fluvoxamine | Vanda Pharmaceuticals | Healthy Volunteers | 03/12 | 03/12 | | |
NCT01269333: Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel |
|
|
| Completed | 1 | 15 | RoW | omeprazole, fluvoxamine, placebo | Hadassah Medical Organization | Drug Interaction of Clopidogrel | 07/12 | | | |
NCT01665404: A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers |
|
|
| Completed | 1 | 16 | Europe | Fluvoxamine, RO4917523 | Hoffmann-La Roche | Healthy Volunteer | 09/12 | 09/12 | | |
NCT01704638: Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes |
|
|
| Completed | 1 | 14 | Europe | fluvoxamine, Digoxin | Karolinska Institutet | Depression | 10/12 | 10/12 | | |
NCT01707407: A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects |
|
|
| Completed | 1 | 32 | US | Pomalidomide, (CC-4047), Ketoconazole, Fluvoxamine, Carbamazepine | Celgene | Pharmacology, Clinical, Healthy | 11/12 | 11/12 | | |
NCT01396720: Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel |
|
|
| Completed | 1 | 15 | RoW | fluvoxamine, citalopharm | Hadassah Medical Organization | Drug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors | 12/12 | 12/12 | | |
CTKI258A2120, NCT01700270: Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. |
|
|
| Completed | 1 | 45 | Europe, US | dovitinib (TKI258), fluvoxamine | Novartis Pharmaceuticals | Advanced Solid Tumors, Excluding Breast Cancer | 08/14 | 08/14 | | |
NCT02853136: Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 |
|
|
| Completed | 1 | 18 | Europe | Fluvoxamine, BI 409306 | Boehringer Ingelheim | Healthy | 10/16 | 10/16 | | |
NCT03340662: Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122 |
|
|
| Completed | 1 | 81 | US | CC-122, Itraconazole, Fluvoxamine, Rifampin | Celgene | Healthy Volunteer | 01/18 | 01/18 | | |
| Completed | 1 | 41 | US | TD-9855, Fluvoxamine, Itraconazole, Caffeine | Theravance Biopharma | Drug Drug Interaction (DDI) | 04/18 | 04/18 | | |
NCT03634345: Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. |
|
|
| Completed | 1 | 24 | Europe | Period 1 - Day 1: PF-04965842 administered, Single administration of PF-04965842 in Period 1., Period 2: Cohort 1: Fluvoxamine & PF-04965842, 9-day administration of Fluvoxamine and single administration of PF-04965842 on day 8., Period 2: Cohort 2: Fluconazole & PF-04965842, 7-day administration of fluconazole and single administration of PF-04965842 on day 5. | Pfizer | Dermatitis, Atopic | 12/18 | 12/18 | | |
NCT03930602: Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165 |
|
|
| Completed | 1 | 16 | US | BMS-986165, Fluvoxamine | Bristol-Myers Squibb | Healthy | 05/19 | 05/19 | | |
NCT04478513: A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers |
|
|
| Completed | 1 | 28 | Europe | AZD4635, Fluvoxamine | AstraZeneca, Parexel | Healthy Volunteer/DDI Study | 12/20 | 12/20 | | |
NCT05121714: Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 |
|
|
| Completed | 1 | 59 | Europe | Caffeine, ABX464, Fluvoxamine | Abivax S.A. | Healthy | 05/21 | 05/21 | | |
NCT05532358: A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) |
|
|
| Completed | 1 | 54 | Europe | anle138b (TEV-56286), Caffeine, Midazolam, Fluvoxamine, Fluvoxamine 100 mg QD for 5 days, TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine | MODAG GmbH, Aptuit, Quotient Sciences, Teva Pharmaceutical Industries, Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |
NCT05712265: Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant |
|
|
| Completed | 1 | 26 | US | Miricorilant, CORT118335, Fluvoxamine | Corcept Therapeutics | Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | 02/23 | 02/23 | | |
Switch19, NCT05264142: Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status |
|
|
| Recruiting | 1 | 45 | Europe | Voriconazole 200mg, J02AC03, FluvoxaMINE 50 Mg Oral Tablet, N06AB08, Omeprazole 10 MG Oral Tablet, A02BC01 | University Hospital, Geneva | Healthy | 03/23 | 08/23 | | |
NCT05888207: A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects |
|
|
| Completed | 1 | 16 | US | Savolitinib, Fluvoxamine | AstraZeneca, Parexel | Healthy Male Subjects | 08/23 | 08/23 | | |
NCT06232109: Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects |
|
|
| Recruiting | 1 | 48 | Europe | Fluvoxamine, Itraconazole, Paroxetine, ASN51 | Asceneuron S.A. | Drug Drug Interaction | 05/24 | 05/24 | | |
